Energy expenditure in frontotemporal dementia: a behavioural and imaging study

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Brain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>BRAIN-2016-00843.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Article</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Ahmed, Rebekah; Neuroscience Research Australia, Landin-Romero, Ramon; Neuroscience Research Australia, Collett, Tinh-Hai; Institute of Metabolic Science Van der Klaauw, Agatha; Institute of Metabolic Science Devenney, Emma; Neuroscience Research Australia, ; University of New South Wales, Henning, Elana; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Kiernan, Matthew; University of Sydney, Brain and Mind Research Institute Piguet, Olivier; Neuroscience Research Australia, Farooqi, Sadaf; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Hodges, John; Neuroscience Research Australia,</td>
</tr>
<tr>
<td>Subject category:</td>
<td>Dementia</td>
</tr>
<tr>
<td>To search keyword list, use whole or part words followed by an *:</td>
<td>Frontotemporal dementia &lt; DEMENTIA, Behavioural neurology &lt; NEUROPSYCHIATRY, Autonomic nervous system &lt; NEUROMUSCULAR DISEASES, Amyotrophic lateral sclerosis &lt; NEURODEGENERATION: CELLULAR AND MOLECULAR, Dementia: structural MR imaging &lt; DEMENTIA</td>
</tr>
</tbody>
</table>
Energy expenditure in frontotemporal dementia: a behavioural and imaging study

Rebekah M Ahmed MBBS, FRACP, Ramon Landin-Romero PhD, Tinh-Hai Collet MD, Agatha A. van der Klaauw MD PhD, Emma Devenney Elana Henning BSc, Matthew C. Kiernan DSc, Olivier Piguet PhD, I. Sadaf Farooqi MB.ChB, PhD, John R Hodges MD, FRCP.

1Neuroscience Research Australia, Sydney, Australia
2University of New South Wales, Sydney, Australia
3ARC Centre of Excellence in Cognition and its Disorders, the University of New South Wales, Sydney, 2031 Australia
4University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom
5Brain & Mind Centre, Sydney Medical School, University of Sydney, 2000, Australia

Corresponding Author
Dr Rebekah Ahmed and Professor John Hodges
Neuroscience Research Australia,
Barker St, Randwick
NSW 2031, Australia
Phone: +61 29399 1000 Fax: +61 2 9399 1646
E-mail: rebekahahmed@gmail.com and j.hodges@neura.edu.au

Abstract word count: 326
Word count: 5935
References: 72
Figures: 5
Tables: 4
Supplementary files: 3
Key words: Frontotemporal dementia, metabolism, heart rate, physiology, autonomic function.
Abstract

Abnormal eating behaviour and metabolic parameters including insulin resistance, dyslipidaemia and body mass index are increasingly recognized as important components of neurodegenerative disease and may contribute to survival. It has previously been established that behavioural variant frontotemporal dementia is associated with abnormal eating behaviour characterised by increased sweet preference. In this study, it was hypothesized that behavioural variant frontotemporal dementia might also be associated with altered energy expenditure. A cohort of 19 patients with behavioural variant frontotemporal dementia, 13 with Alzheimer’s disease and 16 (age- and sex- matched) healthy controls were studied using Actiheart devices (CamNtech, UK) to assess resting and stressed heart rate. Actiheart devices were fitted for 7 days to measure sleeping heart rate, activity levels, and resting, active and total energy expenditure. Using high resolution structural MRI the neural correlates of increased resting heart rate were investigated including cortical thickness and region of interest analyses. In behavioural variant frontotemporal dementia, resting ($p=.001$), stressed ($p=.037$) and sleeping heart rate ($p=.038$) were increased compared to controls, and resting heart rate ($p=.020$) compared to Alzheimer Disease patients. Behavioural variant frontotemporal dementia was associated with decreased activity levels compared to controls ($p=.002$) and increased resting energy expenditure ($p=.045$) and total energy expenditure ($p=.035$). Increased resting heart rate correlated with behavioural (Cambridge Behavioural Inventory) and cognitive measures (Addenbrooke’s Cognitive Examination). Increased resting heart rate in behavioural variant frontotemporal dementia correlated with atrophy involving the mesial temporal cortex, insula, and amygdala, regions previously suggested to be involved exclusively in social and emotion processing in frontotemporal dementia. These neural correlates overlap the network involved in eating behaviour in frontotemporal dementia suggesting, a complex interaction between eating behaviour, autonomic function and energy homeostasis. As such the present study suggests that increased heart rate and autonomic changes are prevalent in behavioural variant frontotemporal dementia, and are associated with changes in energy expenditure. An understanding of these changes and neural correlates may have potential relevance to disease progression and prognosis.
Introduction

Traditionally Frontotemporal dementia (FTD) has been viewed as a syndrome characterised by behavioural and cognitive changes, although increasingly it is being recognised that there is involvement of networks that affect physiological processing including somatosensory processing including pain and temperature (Fletcher et al., 2015a; Fletcher et al., 2015b), autonomic processing (Ahmed et al., 2015a; Guo et al., 2016), and neuroendocrine and metabolic changes (Ahmed et al., 2014b; Ahmed et al., 2015b). In behavioural variant frontotemporal dementia (bvFTD), eating behavioural changes are common, including hyperphagia, increased sweet preference and changes in food preference that may be associated with increased body mass index (BMI), dyslipidaemia and insulin resistance (Ahmed et al., 2014b).

In several neurodegenerative diseases it is established that there are changes in metabolic parameters. One such condition is ALS, which shares a clinical and pathological overlap with FTD and where consistent changes have been found (Ahmed et al., 2016b), including increased resting energy expenditure in up to 50% of patients (Bouteloup et al., 2009; Vaisman et al., 2009). It has also been suggested that the hypermetabolic state (defined as increased energy expenditure) is intrinsically linked to the process of neurodegeneration with several animal models of TDP-43 and the C9ORF72 gene expansion exhibiting hypermetabolism and weight loss (Dupuis et al., 2004; Chiang et al., 2010; Shan et al., 2010; Xu et al., 2010; Koppers et al., 2015).

Given the significant overlap between FTD and ALS at a clinical, pathological and genetic level, it seems plausible that changes in energy expenditure may also be present in FTD (Ahmed et al., 2016b). In addition, the changes in appetite appear to exceed the minor increments in BMI and weight gain seen in bvFTD, suggesting increased energy expenditure may also contribute to the body weight changes seen in patients (Woolley et al., 2007; Ahmed et al., 2014a). This is also suggested by the fact that in studies measuring caloric intake in FTD, BMI does not correlate with caloric intake (Ahmed et al., 2016a). Energy expenditure, which includes basal metabolic rate (amount of energy expended at rest) and active energy expenditure (a combination of activity levels and heart rate), has not been investigated in bvFTD. Intrinsically linked with energy expenditure are potentially alterations in autonomic
activity including heart rate, heart rate variability, and sympathetic and parasympathetic drive (Messina et al., 2013). Changes in the autonomic nervous system, particularly in the sympathetic nervous system have also been proposed to affect glucose and fat metabolism (Nonogaki, 2000; Penicaud et al., 2000). Increases in heart rate have been found to predict an increase in metabolic rate and energy expenditure, via an increase in circulatory rate and oxygen consumptions (Berggren and Hohwu Christensen, 1950).

Measurement of energy expenditure in free-living individuals is challenging. In this study, we used digital heart rate/activity monitoring (Brage et al., 2004; Brage et al., 2005; Crouter et al., 2008) to examine changes in heart rate (rest, stressed and sleep), activity levels and energy expenditure and the potential correlations that this has to autonomic function in a large group of bvFTD patients, compared to a disease comparison group (Alzheimer’s disease, AD) and healthy controls. This approach has been used previously in genetic obesity research but not in patients with neurodegeneration (Pearce et al., 2013). The potential neurobiological underpinnings of increases in heart rate were further examined using structural MRI imaging to provide insight into the neural correlates controlling energy expenditure and autonomic function in FTD.
Methods

Participants
Thirty-two patients with dementia (19 bvFTD, 13 AD) were recruited from Forefront, Neuroscience Research Australia. These individuals were compared with 16 age- and sex-matched healthy controls. All patients underwent neurological review, cognitive assessment and met current clinical diagnostic criteria for probable bvFTD or AD (McKhann et al., 2001; Gorno-Tempini et al., 2011; McKhann et al., 2011; Rascovsky et al., 2011). Disease severity was established using the Frontal Rating Scale (FRS) (Mioshi et al., 2010). Controls were recruited from the Neuroscience Research Australia Volunteer database. Healthy controls scored above 88/100 on the Addenbrooke’s Cognitive Examination-III (Hsieh et al., 2013) and 0 on the sum of boxes score of the Clinical Dementia Rating scale (Morris, 1993). Exclusion criteria for patients and controls included concurrent psychiatric disturbance, other neurodegenerative conditions or neurological disorders and/or history of substance abuse.

Patient medical history and medications
Patients medical records and list of medications were obtained from their general practitioner. Given that the study measured heart rate variations, patients with a known cardiac rhythm disorder e.g. atrial fibrillation, supraventricular tachycardia or conduction delays were excluded from the study (1 bvFTD and 1 AD patient). Patients, their carers and controls were asked about their current smoking status and alcohol intake.

Ethics
This study was approved by the South Eastern Sydney Local Health District and the University of New South Wales human ethics committees. Written informed consent was obtained from each participant and/or their primary caregiver.

Physiological measurements: Actiheart device
Participants were fitted with the Actiheart device (CamNtech, Cambridge, UK) a compact device designed to quantify heart rate, activity and energy expenditure
The Actiheart has two clips which are attached directly to standard ECG electrodes. One electrode was attached to V1 on the chest (4th right intercostal space) and the second electrode was placed 10 cm away on the left mid-clavicular line. The number of R waves detected is recorded at 15-second epochs and from this the heart rate is derived. An internal triaxial accelerometer senses the frequency and intensity of the participant’s torso movements including walking and pacing from which activity counts are derived. When placed in short term mode, the Actiheart measures heart rate variability, heart rate and inter-beat interval (IBI) of the heart rate, with an epoch length of 15 seconds. Long term recordings in long term mode provide mean heart rate and activity levels over an epoch of 15 seconds and recordings can be made for up to 11 days (Brage et al., 2004; Brage et al., 2005; Crouter et al., 2008).

Measurement of heart rate
To measure resting and stressed heart rate participants wore the Actiheart in short term recording mode for a period of 6 hours following a standard protocol, described briefly. After arriving fasted (10 hours) and an initial period of introduction patients were given a set breakfast that measured caloric intake (Ahmed et al., 2016a), no caffeine or tea was included in this breakfast to avoid their chronotropic effects. Participants were then asked to rest in a lounge environment and their resting heart rate was obtained over a period of 30 minutes. Following this, participants were then taken into a room and took part in 2 hours of cognitive testing. The initial 30 minutes of this period was taken as the stressed heart rate. Resting and stressed heart rates and measures of autonomic function were obtained after entering the beat-to-beat RR interval data obtained by the Actiheart into Kubios HRV, an advanced and easy to use software for heart rate variability (HRV) analysis (Tarvainen et al., 2014). The following measures were obtained: the root mean squared of successive differences (RMSSD), which is a measure of vagal control of the heart (DeGiorgio et al., 2010); the low frequency (LF), which corresponds to the 0.10Hz slow fluctuations of arterial pressure and reflects sympathetic and parasympathetic tone; the high frequency (HF) which corresponds to ~0.25 Hz fluctuations and is a measure of respiratory sinus arrhythmias and can be considered an index of vagal modulation; and the LF/HF ratio which is used to indicate balance between sympathetic and parasympathetic tone.
Long term actiheart recordings
Following the short term analyses, participants were fitted with the Actiheart in long term mode and asked to wear this at home for 7 days to provide continuous heart rate and activity monitoring. The participants wore the device continuously and were allowed to shower with the device. Carers were given instructions to refit the device if it became loose or was removed. From the long-term recording, sleeping heart rate and activity counts were calculated.

Measurement of sleeping heart rate
Sleeping heart rate was calculated over a period of 1 night. For each participant, the 1 night was selected from the 7 day long term recording where a period of recording of uninterrupted sleep was obtained, between midnight and 5 am where no activity was detected. From this period, the average sleeping heart rate, minimum and maximum heart rate was calculated for each participant. Investigators were blinded to the patient ID and diagnoses for this selection.

Measurement of activity over 24 hours
An average activity count over 24 hours was calculated for each participant. This was obtained by selecting a 24-hour period in the 7 day long-term recording where continuous recording was available for each patient. This was found to be day 2 in each patient as the Actiheart had been firmly attached and had not been removed, which tended to occur as the long term recording proceeded. The average activity counts for each patient over these 24 hours was obtained and expressed as an activity count per 24 hours. Significance levels between group means were examined after correcting for age and sex.

Measurement of energy expenditure
The Actiheart measures heart rate and activity simultaneously and these data are transferred to the Actiheart software which uses a validated branched model equation (Brage et al., 2004; Brage et al., 2005) to derive active energy expenditure for each epoch using a combination of heart rate and activity. Using the branched model equation, group Cal JAP2007 (CamNtech, Cambridge, UK) measures of daily energy expenditure were calculated for each participant each day for 7 days and an average over this period obtained. The following measures were obtained: Active Energy
expenditure (AEE) derived from the branched model equation, which includes a combination of heart rate and activity measures; Resting energy expenditure (REE) derived from the Schofield equation, designed to measure basal metabolic rate adjusted for weight (Schofield, 1985); Dietary induced thermogenesis (DIT), estimated as 10% of total energy expenditure; Total energy expenditure (TEE) = REE + AEE + DIT; Physical activity level (PAL) = TEE/REE.

**Behavioural measurements**

In addition to measurements of heart rate variability, activity and energy expenditure, changes in eating behaviour were measured using caregiver-based questionnaires: the Appetite and Eating Habits Questionnaire (APEHQ) (Ikeda et al., 2002; Ahmed et al., 2014a) and the Cambridge Behavioural Inventory (CBI) (Bozeat et al., 2000). These surveys were completed on the same day the short term recordings were obtained and were felt to be representative of intake over the proceeding 7 days when the long term recordings were obtained. The APEHQ provides measures of nicotine and alcohol consumption. Height and weight were measured barefoot and body mass index (BMI) calculated (weight in kilograms/height in metres squared).

**Imaging**

**MRI acquisition and preprocessing**

All participants underwent whole brain structural MRI with a 3 T Phillips scanner using a standard 8-channel head coil. 3D high-resolution turbo field echo T1-weighted sequences were acquired with the following parameters: coronal orientation, matrix 256 × 256, 200 slices, 1 mm² in-plane resolution, slice thickness 1 mm, echo time/repetition time 2.6/5.8 ms, flip angle α=8°. MRI scans were obtained on the same day as the physiological and behavioural assessment.

Before analyses, the two T1 volumes were merged and averaged to increase the signal to noise ratio and the grey matter-white matter contrasts in brain structures. FreeSurfer software, version 5.3.0 (http://surfer.nmr.mgh.harvard.edu) was used for surface-based cortical processing (Dale et al., 1999; Fischl et al., 1999) using standard methods (Fischl and Dale, 2000). Cortical thickness was smoothed with a 20 mm full-width at half-height Gaussian kernel. This level of blurring kernel was chosen to
reduce the impact of imperfect alignment between cortices and thereby improve the signal-to-noise ratio (Lerch and Evans, 2005).

In addition, the following subcortical structures were automatically segmented and extracted for both hemispheres: thalamus, caudate, putamen, globus pallidus, hippocampus, amygdala, and nucleus accumbens. For these subcortical structures, measurements from both hemispheres were averaged and adjusted for total intracranial volume, in line with previous methodology (Voevodskaya et al., 2014).

All the resulting images were visually inspected and manually corrected in the event of tissue segmentation errors. One bvFTD patient and 2 healthy controls were excluded due to excessive surface or subcortical segmentation errors. Thus, 18 bvFTD, 13 AD and 14 healthy controls were included in the imaging analyses.

**Statistical analyses**

**Demographic and physiological variables**

Analyses were conducted using IBM SPSS statistics (version 21.0). Kolmogorov-Smirnov tests were run to determine suitability of variables for parametric analyses. One-way analyses of variance (ANOVA), followed by Tukey post hoc tests, were used to determine group differences in demographic and clinical variables (age, ACE-R). Categorical variables were analyzed using chi-square analyses. Independent t-tests were used to determine differences between bvFTD and AD for disease duration, abnormal behaviour (total CBI, CBI behavioural) and eating behaviour (APEHQ, CBI eating, and BMI) ($p \leq 0.05$ regarded as significant). Measurements of heart rate (resting and stressed), autonomic function (resting and stressed LF, HF, RMSSD after log transformation), activity counts and energy measures (REE, AEE, DIT, PAL) were also explored using ANOVA, followed by Tukey post hoc tests. The relationship between resting heart rate and disease duration, BMI, eating behaviour (APEHQ total score) cognitive status (ACE-III) and behavioural measures (CBI total, eating and behavioural) were further explored using Pearson rank correlations corrected for multiple comparisons ($p \leq 0.01$ regarded as significant).

**Imaging data analyses**
For cortical thickness, sets of vertex-by-vertex analyses were performed using general linear models aimed to examine differences in cortical thickness between groups and then to estimate the neural correlates for the physiological variables where bvFTD showed significant differences with both AD and healthy controls (resting heart rate and stressed heart rate). In the first set of analyses, overall cortical thickness of both hemispheres was modelled including cortical thickness as a dependent variable and group (bvFTD, AD, healthy controls) as an independent variable. In the second set of analyses, we created separate linear models, one for each physiological variable under examination. Each model included the following repressors: group (bvFTD, AD, healthy controls), the physiological variable (resting heart rate, stressed heart rate) and the interaction between group and the physiological variable. To determine physiological associations with cortical thickness specific to diagnostic group, we focused on the interaction effect between each diagnosis and each physiological variable. Correlations between physiological variables and cortical thickness were investigated first by combining all participants (behavioural variant FTD, AD, Alzheimer’s disease, controls) and then in each patient group combined with controls, to identify neural correlates of resting and stressed heart rate to each patient group.

Since the groups were matched at baseline for age, sex and duration of disease, no covariates were included in the models. Statistical significance was set at $p = 0.001$ uncorrected for multiple comparisons. In addition, we used a conservative cluster extent threshold of $k > 50 \text{ mm}^2$. This approach is designed to minimize Type I error while balancing the risk of Type II error (Lieberman and Cunningham, 2009).

For the subcortical regions, group comparisons of subcortical volumes between bvFTD, AD and healthy controls were performed using ANOVA. Post hoc analyses were corrected for multiple comparisons using a Sidak adjustment. Next, in order to uncover the subcortical grey matter correlates of resting heart rate and stressed heart rate, correlations were investigated using the same approach outlined above. Pearson two-tailed correlational analyses were conducted with Bonferroni correction for multiple comparisons ($p < \alpha/k = .007$).

**Region of interest analyses**

In addition to the whole-brain analyses, a set of cortical regions of interest (ROI) were selected and computed and averaged from the regional parcellations provided by FreeSurfer for both hemispheres. These regions were selected according to previous
findings in the literature examining associations between autonomic function (e.g., pain and temperature and heart rate) and brain regions in bvFTD and AD and normal controls (Critchley et al., 2003; Jones, 2011; Fletcher et al., 2015a). The regions selected included the prefrontal, mesial temporal and anterior cingulate cortices, and the insula. Details on the computation of these measurements can be found in Supplementary Table S1. Pearson two-tailed correlations were used to examine associations between these ROIs and the resting and stressed heart rate. These analyses were Bonferroni corrected to control for multiple comparisons ($p < \alpha/k = .0125$).
Results

Participants groups were representative of the diseases studied and did not differ in sex distribution, age or disease duration (Table 1, all $p$ values > 0.365). Group differences were observed on measures of cognition (ACE-III), behavioural measures and eating behaviour (Table 1) and were in keeping with the known behaviour of the diagnostic groups. On the ACE-III as expected the patient groups scored lower than controls ($p < .001$). The bvFTD group was more functionally impaired relative to AD (FRS; $t = 3.3, p = .03$). The bvFTD group as expected scored higher than the AD group on the total CBI score ($t = 3.6, p = .001$), and CBI behavioural score ($t = 4.1, p < .001$).

Medications, smoking and alcohol intake (Table 1)

As expected, a higher number of AD patients were on cholinesterase inhibitors (9 patients) compared to the bvFTD (2 patients) and control (no patient) groups. There was no difference in the number of patients treated with a medication likely to affect heart rate and cardiac conduction (e.g. beta blocker, calcium channel blocker) between the groups. One bvFTD patient was on stable and adequate thyroxine treatment. Two bvFTD patients and 2 control subjects were current smokers. Eight bvFTD patients carers reported that they consumed alcohol normally, less than weekly in 4 and several times per week in 4. Ten control subjects reported alcohol consumption, 4 less than weekly and 6 several times a week. Five AD patients reported alcohol intake regularly, 2 several times a week and 3 less than weekly. No patient or control participant stated that they consumed more alcohol than the recommended amount by the Australian National Health and Medical research council.

Eating behaviour and BMI

On both the APEHQ and CBI eating score the bvFTD group showed more severe eating disturbance based on caregiver surveys compared with AD ($t = 4.1, p < .001$). The bvFTD group had an increased BMI (Figure 1) compared to the AD ($p = .001$) and Control groups ($p = .008$) (Table 1).

[INSERT FIGURE 1 HERE]
Heart rate and autonomic function

Significant group differences were present for both resting ($F= 8.6$, $p = .001$) and stressed ($F= 3.2$, $p = .047$) heart rate measures. The bvFTD group (mean = 81.8 bpm had an increased resting heart rate compared to both the control (mean= 68.5 $p = .001$) and AD groups (mean = 72.5, $p = .020$) and an increased stressed heart rate compared to the control group (bvFTD = 81.5, AD= 76.1, Control= 71.9; $p = .037$) (Figure 2). On measures of autonomic function (Table 2), no significant group differences were detected; however, a trend for the bvFTD group to have a decreased RMSSD value, in both resting ($p = .076$) and stressed states ($p = .063$) was present.

Correlations of resting heart rate with behavioural measures

When all groups were combined, resting heart rate was positively correlated with behavioural and eating changes as reflected by the CBI total ($r = .417$, $p = .004$), CBI behavioural ($r = .451$, $p = .001$), and total CBI eating score ($r = .307$, $p = .01$), and negatively correlated with cognitive function on the ACE-III ($r = -.314$, $p = .01$), functional ability on the FRS ($r = -.308$, $p = .05$). As in prior studies, an increased BMI correlated with behavioural changes on the CBI total ($r = .369$, $p = .01$), CBI behavioural ($r = .334$, $p = .01$), and total CBI eating score ($r = .397$, $p = .006$), and the APEHQ ($r = .461$, $p = .01$). BMI did not correlate with resting heart rate ($r = .206$, $p = .160$).

Long term actiheart recordings

Long-term recordings over 7 days were obtained for 12 bvFTD, 10 AD, and 11 control participants to measure sleeping heart rate and activity levels. Several bvFTD patients refused to wear the Actiheart or when at home disposed of it. The patients in the subset analyses did not differ from the larger group in which short term recordings and imaging correlation were conducted.

Sleeping heart rate

As with resting and stressed heart rate significant group differences were also detected in mean sleeping heart rate (Figure 3a) ($F = 3.9$, $p = .032$) with the bvFTD
group (mean= 71.6 bpm) having an increased sleeping heart rate compared to the control group (mean= 61.5 p = .038) and a trend compared to the AD group (mean = 62.8 p = .085). No group differences (F = 1.4 p = .270) in mean minimum heart rate were detected between the bvFTD (58.9 ± 7.3 bpm), AD (54.7 ± 8.2) and control groups (55.1 ± 5.2). By contrast, the bvFTD group (100.2 ± 13.9) had an increased maximum heart rate compared to the control group (95.7 ± 14.3 bpm; F= 4.2 p= .025).

**Activity levels**

Group differences were detected on activity counts (Figure 3b) over a 24 hour period, after correcting for age and sex. Contrary to what was expected both the bvFTD (p = .002) and AD groups (p=.05) showed significantly decreased activity counts per hour compared with the controls, suggesting particularly that the bvFTD group has reduced activity levels.

[INSERT FIGURE 3 HERE]

**Energy expenditure**

On examination of energy expenditure group differences were present (Table 3), with the bvFTD group having an increased resting energy expenditure compared to the control (p=. .045) and AD (p=. .005) groups. The bvFTD group also had an increased diet induced thermogenesis and total energy expenditure compared to the other groups. Despite the finding of decreased activity counts in bvFTD, no significant group differences in active energy expenditure were observed (calculated as a combination of heart rate and activity levels), suggesting that the decreased activity counts in bvFTD may not have affected the active energy expenditure, due to the increased heart rate seen in this group.

**Imaging analyses**

**Atrophy analyses**

Group comparisons between each clinical group and controls revealed the characteristic profiles of brain atrophy previously reported as consistent with a diagnoses of bvFTD and AD. These results are presented in Supplementary Figure S1
and Supplementary Table S2. In brief, bvFTD patients showed atrophy in the insula
and inferior frontal and anterior temporal cortices. In contrast, AD patients
demonstrated widespread and bilateral atrophy involving parietal, temporal and to a
lesser extent frontal regions, compared with controls. In addition, both clinical groups
showed atrophy in all subcortical structures measured compared with controls, with
the exception of the thalamus and the globus pallidus (Supplementary Table S2). The
amount of atrophy in these structures was of similar magnitude in bvFTD and AD.

**Neural correlates of resting and stressed heart rate**

Unbiased whole brain analyses yielded a significant association between increasing
resting heart rate and cortical thinning in the right posterior cingulate and right
inferior parietal cortex when combining bvFTD and AD patients together (Figure 4).

![INSERT FIGURE 4 HERE]

In bvFTD but not in AD, increased resting heart rate was associated with volume
reductions in the thalamus ($r = -.349, p = .05$), caudate ($r = -.334, p = .06$), putamen ($r
= -.342, p = .05$), hippocampus ($r = -.529, p = .002$), amygdala ($r = -.353, p = .04$) and
nucleus accumbens ($r = -.446, p = .01$), structures which are known in normal
controls to be involved in autonomic regulation. Of these correlations, only the
association between reduced hippocampal volume and increased resting heart rate
survived conservative Bonferroni correction for multiple comparisons (Table 4).

![INSERT TABLE 4 HERE]

Also in bvFTD but not in AD, ROI analyses uncovered significant associations
between increased resting heart rate and cortical thinning in the mesial temporal
cortex ($r = -.520, p = .002$) and the insula ($r = -.490, p = .004$). Additional correlations
were also found with the prefrontal ($r = -.359, p = .04$) and anterior cingulate cortices
($r = -.352, p = .04$), again structures known to be integral to autonomic control,
although these did not survive correction for multiple comparisons (Figure 5).

![INSERT FIGURE 5 HERE]
No further significant associations were found between stressed heart rate and cortical or subcortical regions in either bvFTD or AD.

**Discussion**

Behavioural variant frontotemporal dementia is characterized by an increased resting, stressed and sleeping heart rate compared to both AD and healthy controls. Given that changes in heart rate are indicative of changes in metabolic rate and energy expenditure (Berggren and Hohwu Christensen, 1950; Penzel et al., 2003), via the relationship between pulse rate, circulation and oxygen consumption, these changes suggest the presence of a hypermetabolic state in bvFTD. Behavioural variant frontotemporal dementia is also characterised by increased resting energy expenditure, total energy expenditure and decreased activity levels. Changes in heart rate correlate to a neural network involving the mesial temporal cortex, insula, nucleus accumbens and cingulate.

In ALS, which overlaps clinically, pathologically and genetically with bvFTD, changes in heart rate (Chida et al., 1989) and a state of hypermetabolism (Desport et al., 2001) have also been documented, with an increased heart rate on formal autonomic function testing being found secondary to increased sympathetic and decreased parasympathetic input (Chida et al., 1989). In the present study, indications of decreased vagal tone and parasympathetic input in bvFTD were also present, with a trend towards decreased RMSSD, which is a measure of heart rate variability and reflects the integrity of vagus nerve mediated control of the heart (DeGiorgio et al., 2010). There is good experimental evidence in rodents and humans that changes in autonomic tone induced directly or indirectly (for example through thyroid disorders) affect energy expenditure and peripheral metabolism (lipolysis) (Nonogaki, 2000; Penicaud et al., 2000; Messina et al., 2013). It is therefore readily plausible that changes in heart rate may alter energy expenditure in patients with FTD. However, this remains to be established in studies using indirect calorimetry although we note these can be quite challenging in patients with complex behavioural problems.
Anecdotally, patients with bvFTD are described as being restless with pacing behaviour or alternatively to show inertia (Piguet et al., 2009), but activity levels have not been systematically examined. It has also been suggested that bvFTD patients may not show the degree of weight gain expected in the setting of their increased eating due to hyperactivity (Woolley et al., 2007). Here, however, we have demonstrated that bvFTD patients show decreased activity levels compared with healthy controls. This decreased activity may be secondary to the increased apathy seen in this disorder, which has been, related to atrophy in the right caudate, ventral striatum and cortical basal ganglia circuits (Eslinger et al., 2012), brain regions commonly affected in bvFTD.

In addition, bvFTD patients exhibited an increased resting energy expenditure (REE), a measure of the resting metabolic rate, and total energy expenditure. The increased REE and basal metabolic state may in part be explained by the increased body mass index seen in the bvFTD group, but may also be influenced by the presence of a hypermetabolic state. This finding is in keeping with results in ALS showing that ALS patients may show total energy expenditure well above their REE and activity levels and potentially secondary to hypermetabolism (Kasarskis et al., 2014).

Increased resting heart rate was also found to correlate with increasing cognitive impairment (lower ACE-III scores) and increasing behavioural impairment (higher CBI scores). Changes in neurodegeneration have been linked to alterations in energy homeostasis with animal models of ALS and FTD associated with weight loss and hypermetabolism (Dupuis et al., 2004; Chiang et al., 2010; Shan et al., 2010; Xu et al., 2010). Additional studies in patients with the language variants of FTD, particularly Semantic dementia may be informative. It is suspected that there may well be changes in energy expenditure in semantic dementia given that they have similar changes in BMI to bvFTD in the context of eating behavioural changes (Ahmed et al 2014) and a similar pathology to ALS (TDP-43), where energy changes are prominent (Dupuis et al., 2011; Ahmed et al., 2016b).

It may be suggested that the changes seen in heart rate in bvFTD i.e. an increased resting and stressed and sleeping heart may be secondary to environmental factors such as caffeine, nicotine or alcohol consumption. This seems unlikely given that
there was no difference in reported smoking frequency and alcohol consumption between the groups, with only 2 bvFTD and 2 control subjects reported to be smokers, and similar rates of reported regular alcohol consumption, which were within recommended national guidelines. It is also unlikely that caffeine and tea intake would have affected the short term heart rate recordings (resting and stressed heart rate) as patients attended fasted and then received a breakfast with no caffeine available. Caffeine and tea intake was not measured during the long term measurements and this could potentially confound the long term recordings, however this is unlikely given that resting heart was elevated in the setting of the controlled environment of no caffeine consumption for the short term recordings. When considering these results, it should be noted that changes in heart rate may potentially be related to decreased physical fitness associated with increasing disease severity, decreased activity secondary to apathy or loss of independence. However as increases in heart rate did not correlate with BMI changes, this suggests that changes in heart rate are far more complex than just being related to physical fitness and likely represent a complex interaction between atrophy in key cortical areas affecting autonomic function, and energy expenditure, and are likely to be centrally rather than peripherally mediated.

Whilst medications that potentially affect heart rate may affect the results of our study, there was no significant difference in use of chronotropic drugs between the groups. Cholinesterase inhibitor treatment has been linked with bradycardia in a small proportion of patients (Hernandez et al., 2009). Despite the high number of AD patients on this medication, this is unlikely to be a confounding issue in the current study as the mean resting heart rate in the AD group was above that seen in the normal control population.

In this study, an increased resting heart rate in bvFTD was found to correlate with atrophy of the mesial temporal cortex including hippocampus, together with the amygdala, nucleus accumbens, insula and cingulate, all structures known to be integral to autonomic control of the human body and involving the limbic system, which is known to be involved in FTD (Seeley et al., 2008; Jones, 2011). In bvFTD, pathological changes in these structures have traditionally being linked to disturbance of memory and social cognition (Galton et al., 2001; Kipps et al., 2009; Kumfor et al.,
Recently decreased cardiac vagal tone has been found in bvFTD and linked to reduced agreeableness and a network involving left-lateralized functional and structural frontoinsular and cingulate cortex deficits (Guo et al., 2016). Our findings suggest that in addition these structures may have a fundamental role in autonomic, energy expenditure and metabolic control in bvFTD.

The anterior cingulate cortex, has been shown to participate in decision making, response selection (Devinsky et al., 1995), anticipation of reward, task reinforcement (Amiez et al., 2006; Rushworth et al., 2007) and in controlling visceromotor, endocrine and skeletomotor outputs (Vogt et al., 1992), potentially via integration of cognitive with autonomic information (Critchley et al., 2001). In healthy individuals, activity of the anterior cingulate cortex has been associated with increased body mass index (Volkow et al., 2009) suggesting a role for this structure in regulating eating and metabolism. It has also been shown that the anterior cingulate cortex is related to sympathetic modulation of heart rate dissociable from cognitive and motor related activity and that focal damage to brain region can result in both an increase and decrease in heart rate (Critchley et al., 2003). Although the cingulate cortex responds to emotional stimuli, it is also metabolically active at rest (Raichle et al., 2001; Luu and Posner, 2003), suggesting a pivotal role for this brain region in the normal physiological control of the body.

Several studies and meta-analyses have shown the integral role that the amygdala plays in controlling heart and heart rate variability, particularly in times of emotional response and threat (Thayer et al., 2012). The fact that the amygdala correlated with increased resting heart rate in bvFTD in the current study, suggests that this structure plays a role in the physiological and metabolic changes seen in bvFTD and not simply in response to emotional stimuli. The insula is involved early in the course of bvFTD (Seeley et al., 2008) and has been found on voxel-based morphometry (VBM) to correlate to pain and temperature symptoms in bvFTD, with the suggestion that it forms a network hub for sensory homeostatic signalling with the thalamus in bvFTD. (Fletcher et al., 2015a). Our findings suggest that the insula also forms an important part of the network involved in heart rate, energy expenditure, autonomic and metabolic control in bvFTD.
It is of interest that several of the structures found to correlate with increased resting heart rate namely the cingulate cortex, insula and amygdala have been found to correlate with hyperphagia and abnormal eating behaviour in bvFTD. Moreover all of these structures have connections to the hypothalamus (Kullmann et al., 2014; Ahmed et al., 2016a), which has been found to be atrophied in bvFTD and correlate with BMI measures (Ahmed et al., 2015b). This suggests a complex interaction between cortical, subcortical structures and the hypothalamus in the control of eating behaviour, heart rate and energy expenditure all of which are affected in bvFTD.

In AD, by contrast, it has been speculated that weight loss occurs with disease progression and low body weight has previously being correlated to mesial temporal cortex atrophy (Grundman et al., 1996). Further studies using direct measurements of energy intake and expenditure in large numbers of patients and age-and BMI-matched controls (both normal and AD patients) longitudinally are required to assess the relative contributions of these parameters to weight changes in FTD.

Behavioural variant frontotemporal dementia is characterized by an increased resting and sleeping heart rate indicative of changes in metabolic rate and resting energy expenditure which may moderate the weight gain in the setting of prominent changes of eating behaviour. BvFTD is also accompanied by decreased activity levels suggesting that energy expenditure changes are likely secondary to intrinsic processes, driven by changes in heart rate, rather than by an increase in activity levels. Changes in heart rate correlated with atrophy of cingulate and limbic systems including the insula and amygdala, which overlap with networks known to control eating behaviour in bvFTD. Further studies are required to document changes in heart rate and energy expenditure across the ALS-FTD spectrum and in presymptomatic genetic cohorts, to ascertain when changes first develop during the course of the disease. An approach combining longitudinal clinical studies and animal models of FTD and ALS will prove crucial. The current study is the first study to measure the interaction between heart rate, autonomic function and energy expenditure in FTD, using methods from obesity research that allow for measurements over both short term and long term (7 days) in the patient’s normal environment. Further studies using indirect calorimetry to measure basal metabolic rate and total energy expenditure are warranted to further examine these interactions. An understanding of
the potential changes in energy expenditure, autonomic function and their neural correlates including involvement of the mesial temporal cortex, cingulate cortex, amygdala and insula in energy expenditure aids in the physiological phenotyping of FTD and extends our knowledge of the disease beyond cognition and emotion processing.

**Funding:** This work was supported by funding to Forefront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neurone disease, from the National Health and Medical Research Council of Australia (NHMRC) program grant (#1037746 to MK and JH) and the Australian Research Council Centre of Excellence in Cognition and its Disorders Memory Node (#CE110001021 to OP and JH) and other grants/sources (NHMRC project grant #1003139). We are grateful to the research participants involved with the ForeFront research studies. RA is a Royal Australasian College of Physicians PhD scholar and MND Australia PhD scholar. OP is an NHMRC Career Development Research Fellow (#1022684). ISF is supported by the Wellcome Trust, Medical Research Council, European Research Council, NIHR Cambridge Biomedical Research Centre and The Bernard Wolfe Endowment. AAvdK is supported by the Wellcome Trust. THC is supported by research grants from the Swiss National Science Foundation (PBLAP3-145870, P3SMP3-155318).

**Author disclosures:** The authors declare no competing financial interests

**Author contributions:**
Rebekah Ahmed: study concept, data analyses, manuscript preparation and writing.
Ramon Landín-Romero: data analyses, manuscript preparation and writing.
Tinh-Hai Collet: data analyses, manuscript preparation and writing.
Agatha van der Klaauw: data analyses, manuscript preparation and writing
Emma Devenney: data analyses, manuscript preparation and writing
Elana Henning: data analyses, manuscript preparation and writing
Matthew C Kiernan: data analyses, manuscript preparation and writing
Olivier Piguet: data analyses, manuscript preparation and writing
Sadaf Farooqi: study concept, data analyses, manuscript preparation and writing
John Hodges: study concept, data analyses, manuscript preparation and writing.
References


Berggren G, Hohwu Christensen E. Heart rate and body temperature as indices of metabolic rate during work. Arbeitsphysiologie 1950; 14: 255-60.


Lieberman MD, Cunningham WA. Type I and Type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci 2009; 4: 423-8.


Figure Legends

Figure 1: Scatter plot showing BMI values in bvFTD, AD and healthy controls. Horizontal line represents mean +/- SD. bvFTD > AD and controls (p<.001)

Figure 2. Resting and stressed heart rate in bvFTD, AD and healthy controls
* bvFTD > AD (p = .028), ** bvFTD > Controls (p = .037), *** bvFTD > Controls (p = .001)

Figure 3. Long term Actiheart results
Mean sleeping heart rate. *** bvFTD > controls (p = .038); B) Mean activity counts per 24 hours. * AD< Controls (p = .05), ** bvFTD < Controls (p = .002)

Figure 4. Regions showing significant correlations between cortical thinning and increasing resting heart rate in bvFTD and AD in whole brain imaging analyses. Statistical significance was set at p < .001 uncorrected for multiple comparisons. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer's disease.

Figure 5. Significant associations between cortical thickness in preselected ROIs and resting heart rate in bvFTD and HC. No significant associations were seen in AD and HC. Statistical significance was set at p < .0125 Bonferroni corrected for multiple comparisons. bvFTD = behavioural-variant frontotemporal dementia; HC = Healthy controls

Supplementary Figure S1. Patterns of atrophy in bvFTD and AD versus healthy controls. Blue coloured regions show significant cortical thinning in the patient groups compared to controls (p < .05 FDR corrected). Red coloured regions show
significantly increased cortical thickness in the patient group compared to controls (p < .05 FDR corrected).
<table>
<thead>
<tr>
<th></th>
<th>bvFTD (n = 19)</th>
<th>AD (n = 13)</th>
<th>HC (n = 16)</th>
<th>F value</th>
<th>p value</th>
<th>Post hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (F:M)</td>
<td>8:11</td>
<td>7:6</td>
<td>6:10</td>
<td>.83†</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 ± 6.7</td>
<td>66 ± 8.2</td>
<td>65 ± 7.7</td>
<td>1.1</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.0 ± 6.9</td>
<td>23.6 ± 3.1</td>
<td>27.2 ± 5.9</td>
<td>9.6</td>
<td>*p &lt; .001</td>
<td>bvFTD &gt; AD, HC</td>
</tr>
<tr>
<td>ACE-III Total (max 100)</td>
<td>67.1 ± 20.7</td>
<td>64.3 ± 11.2</td>
<td>95.1 ± 1.9</td>
<td>21.6</td>
<td>*p &lt; .001</td>
<td>HC &gt; patients</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>3.5 ± 1.9</td>
<td>4.7 ± 4.5</td>
<td>-</td>
<td>.972#</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>FRS Rasch score^</td>
<td>-1.7 ± 1.2</td>
<td>-.02 ± 1.4</td>
<td>-</td>
<td>17.7#</td>
<td>*p &lt; .01</td>
<td>bvFTD &lt; AD</td>
</tr>
<tr>
<td>APEHQ Total</td>
<td>68.9 ± 38.6</td>
<td>15.1 ± 20.2</td>
<td>-</td>
<td>4.1#</td>
<td>*p &lt; .001</td>
<td>bvFTD &gt; AD</td>
</tr>
<tr>
<td>CBI Total</td>
<td>86.3 ± 24.7</td>
<td>51.3 ± 27.3</td>
<td>-</td>
<td>3.6#</td>
<td>*p &lt; .01</td>
<td>bvFTD &gt; AD</td>
</tr>
<tr>
<td>CBI eating Total</td>
<td>9.3 ± 3.8</td>
<td>3.2 ± 4.5</td>
<td>-</td>
<td>4.1#</td>
<td>*p &lt; .001</td>
<td>bvFTD &gt; AD</td>
</tr>
<tr>
<td>Treatment with cholinesterase inhibitor (n)</td>
<td>2</td>
<td>9</td>
<td>0</td>
<td>22.2†</td>
<td>*p &lt; .001</td>
<td>AD &gt; bvFTD and HC</td>
</tr>
<tr>
<td>Treatment with chronotropic medication (n)</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>.21†</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Current smokers (n)</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>1.7†</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Alcohol consumption (n)</td>
<td>8</td>
<td>5</td>
<td>10</td>
<td>2.1†</td>
<td>ns</td>
<td>-</td>
</tr>
</tbody>
</table>
Values are expressed as mean ± standard deviation. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease; HC = healthy controls; BMI = body mass index; ACE-III = Addenbrooke’s Cognitive Examination-III; FRS = Frontotemporal dementia Rating Scale; APEHQ = Appetite and Eating Habits Questionnaire; CBI = Cambridge Behavioural Inventory; ns = not significant. † Chi-square test; # t-value; ^The FRS provides logit scores ranging from 4.12 (very mild) to -4.99 (very severe). n= number of patients normally reporting alcohol and regular smokers. All alcohol consumption was within normal guidelines (see text).
Table 2. Measures of heart rate variability and autonomic function

<table>
<thead>
<tr>
<th></th>
<th>bvFTD (n = 19)</th>
<th>AD (n = 13)</th>
<th>HC (n = 16)</th>
<th>F value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting LF</td>
<td>.06 ± .02</td>
<td>.07 ± .02</td>
<td>.06 ± .01</td>
<td>.38</td>
<td>ns</td>
</tr>
<tr>
<td>Resting HF</td>
<td>.20 ± .08</td>
<td>.20 ± .07</td>
<td>.26 ± .07</td>
<td>2.6</td>
<td>ns</td>
</tr>
<tr>
<td>Resting RMSSD</td>
<td>21.7 ± 11.1</td>
<td>29.2 ± 18.6</td>
<td>41.7 ± 35.1</td>
<td>2.7</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed LF</td>
<td>.08 ± .10</td>
<td>.07 ± .02</td>
<td>.07 ± .03</td>
<td>.10</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed HF</td>
<td>.21 ± .07</td>
<td>.22 ± .09</td>
<td>.22 ± .07</td>
<td>.08</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed RMSSD</td>
<td>23.3 ± 15.3</td>
<td>31.6 ± 17.9</td>
<td>41.7 ± 31.9</td>
<td>2.9</td>
<td>ns</td>
</tr>
<tr>
<td>Rested LF/HF</td>
<td>.34 ± .10</td>
<td>.35 ± .20</td>
<td>.29 ± .14</td>
<td>1.7</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed LF/HF</td>
<td>.48 ± .65</td>
<td>.38 ± .17</td>
<td>.37 ± .15</td>
<td>1.8</td>
<td>ns</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± standard deviation. Statistical analyses performed on Log transformed values. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease; HC = healthy controls; LF= low frequency; HF= high frequency; RMSSD= the square root of the mean squared difference of successive beat to beat intervals and a measure of vagal control of the heart.
Table 3. Average energy expenditure (kcal) per day in bvFTD, AD and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>bvFTD(^a)</th>
<th>AD(^a)</th>
<th>HC(^a)</th>
<th>F value</th>
<th>p value</th>
<th>Post hoc</th>
</tr>
</thead>
</table>
| Resting energy expenditure     | 1656.9 ± 245.0 | 1356.4 ± 170.5 | 1442.1 ± 173.7 | 6.4     | .005    | bvFTD > HC (\(p = .045\))  
|                                |             |         |         |         |         | bvFTD > AD (\(p = .005\))   |
| Active energy expenditure      | 676.9 ± 428.3 | 471.1 ± 278.8 | 525.1 ± 141.1 | 1.3     | .291    |                   |
| Diet induced thermogenesis     | 259.2 ± 53.6 | 202.9 ± 43.9 | 218.3 ± 24.6 | 5.0     | .013    | bvFTD > HC (\(p = .035\))  
|                                |             |         |         |         |         | bvFTD > AD (\(p = .013\))   |
| Total energy expenditure       | 2592.4 ± 533.9 | 2028.5 ± 440.9 | 2182 ± 246.4 | 5.0     | .013    | bvFTD > HC (\(p = .035\))  
|                                |             |         |         |         |         | bvFTD > AD (\(p = .013\))   |
| Physical activity level        | 1.6 ± .3    | 1.5 ± .1 | 1.5 ± .1 | .6      | .531    |                   |

Values are expressed as mean ± standard deviation. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease; HC = healthy controls. "Missing data: Data missing for 7 bvFTD, 3 AD and 5 HC."
<table>
<thead>
<tr>
<th>Subcortical Structure</th>
<th>bvFTD</th>
<th>AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalamus</td>
<td>-.349*</td>
<td>.031</td>
</tr>
<tr>
<td>Caudate</td>
<td>-.334</td>
<td>.173</td>
</tr>
<tr>
<td>Putamen</td>
<td>-.342*</td>
<td>.159</td>
</tr>
<tr>
<td>Pallidum</td>
<td>-.197</td>
<td>.257</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>-.529**</td>
<td>.056</td>
</tr>
<tr>
<td>Amygdala</td>
<td>-.352*</td>
<td>-.004</td>
</tr>
<tr>
<td>Accumbens</td>
<td>-.446*</td>
<td>.026</td>
</tr>
</tbody>
</table>

Values as expressed in Pearson’s correlation coefficient scores. * Denotes that the correlation is significant at the 0.05 level. ** Denotes that the correlation is significant at the 0.01 level. Significant correlations after correction for multiple comparisons are highlighted in bold. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease. Statistical significance was set at p < .007 Bonferroni corrected for multiple comparisons.
Figure 1: Scatter plot showing BMI values in bvFTD, AD and healthy controls. Horizontal line represents mean +/- SD. bvFTD > AD and controls (p<.001)
Figure 2. Resting and stressed heart rate in bvFTD, AD and healthy controls
*bvFTD > AD (p = .028), ** bvFTD > Controls (p = .037), *** bvFTD > Controls (p = .001)
Figure 3. Long term Actiheart results
Mean sleeping heart rate. *** bvFTD > controls (p=.038); B) Mean activity counts per 24 hours. * AD < Controls (p=.05), ** bvFTD < Controls (p=.002)
Figure 4. Regions showing significant correlations between cortical thinning and increasing resting heart rate in bvFTD and AD in whole brain imaging analyses. Statistical significance was set at $p < .001$ uncorrected for multiple comparisons. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer's disease.

$P$ value
Figure 5. Significant associations between cortical thickness in preselected ROIs and resting heart rate in bvFTD and HC. No significant associations were seen in AD and HC. Statistical significance was set at p < .0125 Bonferroni corrected for multiple comparisons. bvFTD = behavioural-variant frontotemporal dementia; HC = Healthy controls.
**Supplementary table S1.** Component sub-regions for cortical regions of interest analyses

<table>
<thead>
<tr>
<th>Component sub-regions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prefrontal cortex</strong></td>
</tr>
<tr>
<td>Caudal middle frontal, rostral middle frontal, medial orbitofrontal, lateral orbitofrontal, pars opercularis, pars orbitalis and pars triangularis</td>
</tr>
<tr>
<td><strong>Mesial temporal cortex</strong></td>
</tr>
<tr>
<td>Fusiform, entorhinal, parahippocampal and lingual temporal regions</td>
</tr>
<tr>
<td><strong>Anterior cingulate cortex</strong></td>
</tr>
<tr>
<td>Caudal anterior cingulate and rostral anterior cingulate</td>
</tr>
<tr>
<td><strong>Insula</strong></td>
</tr>
<tr>
<td>Anterior (inferior and superior) and posterior insular regions</td>
</tr>
</tbody>
</table>

Component sub-regions were identical in both hemispheres.
**Supplementary Table S2.** Measurements of subcortical brain regions in bvFTD, AD and healthy controls

<table>
<thead>
<tr>
<th>Brain measure</th>
<th>bvFTD (n = 18)</th>
<th>AD (n = 13)</th>
<th>HC (n = 14)</th>
<th>p value</th>
<th>Post hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalamus</td>
<td>4.5 ± 0.8</td>
<td>4.5 ± 0.6</td>
<td>5.0 ± 0.6</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Caudate</td>
<td>1.8 ± 0.7</td>
<td>2.2 ± 0.2</td>
<td>2.4 ± 0.4</td>
<td>0.01</td>
<td>bvFTD, AD &lt; HC</td>
</tr>
<tr>
<td>Putamen</td>
<td>2.8 ± 0.6</td>
<td>3.0 ± 0.4</td>
<td>3.6 ± 0.5</td>
<td>0.001</td>
<td>bvFTD, AD &lt; HC</td>
</tr>
<tr>
<td>Globus Pallidus</td>
<td>0.9 ± 0.2</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.2</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>2.4 ± 0.6</td>
<td>2.2 ± 0.6</td>
<td>3.1 ± 0.3</td>
<td>&lt; 0.001</td>
<td>bvFTD, AD &lt; HC</td>
</tr>
<tr>
<td>Amygdala</td>
<td>1.0 ± 0.3</td>
<td>0.9 ± 0.2</td>
<td>1.3 ± 0.2</td>
<td>0.001</td>
<td>bvFTD, AD &lt; HC</td>
</tr>
<tr>
<td>Nucleus Accumbens</td>
<td>0.2 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>&lt; 0.001</td>
<td>bvFTD, AD &lt; HC</td>
</tr>
</tbody>
</table>

Values are expressed as a ratio of the total intracranial volume (mean ± standard deviation). ns = p > .05.; bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease; HC = Healthy controls.
Energy expenditure in frontotemporal dementia: a behavioural and imaging study

Rebekah M Ahmed MBBS, FRACP1,2,3,5, Ramon Landin-Romero PhD1,2,3, Tinh-Hai Collet MD4, Agatha A. van der Klaauw MD PhD4, Emma Devenney1,2,3,5, Elana Henning BSc5, Matthew C. Kiernan DSc5, Olivier Piguet PhD1,2,3, I. Sadaf Farooqi MBChB, PhD4, John R Hodges MD, FRCP1,2,3.

1Neuroscience Research Australia, Sydney, Australia
2University of New South Wales, Sydney, Australia
3ARC Centre of Excellence in Cognition and its Disorders, the University of New South Wales, Sydney, 2031 Australia
4University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom
5Brain & Mind Centre, Sydney Medical School, University of Sydney, 2000, Australia

Corresponding Author
Dr Rebekah Ahmed and Professor John Hodges
Neuroscience Research Australia,
Barker St, Randwick
NSW 2031, Australia
Phone: +61 29399 1000 Fax: +61 2 9399 1646
E-mail: rebekahahmed@gmail.com and j.hodges@neura.edu.au

Abstract word count: 3215
Word count: 49845
References: 72
Figures: 54
Tables: 4
Supplementary files: 3

Key words: Frontotemporal dementia, metabolism, heart rate, physiology, autonomic function.
**Abstract**

Abnormal eating behaviour and metabolic parameters including insulin resistance, dyslipidaemia and body mass index are increasingly recognized as important components of neurodegenerative disease and may contribute to survival. It has previously been established that behavioural variant frontotemporal dementia is associated with abnormal eating behaviour characterised by increased sweet preference. In this study, it was hypothesized that behavioural variant frontotemporal dementia might also be associated with altered energy expenditure. A cohort of 19 patients with behavioural variant frontotemporal dementia (bvFTD), 13 with Alzheimer’s disease and 16 (age- and sex- matched) healthy controls were studied using Actiheart devices (CamNtech, UK) to assess resting and stressed heart rate. Actiheart devices were fitted for 7 days to measure sleeping heart rate, activity levels, and resting, active and total energy expenditure. Using high resolution structural MRI the neural correlates of increased resting heart rate were investigated including cortical thickness and region of interest analyses. In behavioural variant frontotemporal dementia, resting ($p = .001$), stressed ($p = .037$) and sleeping heart rate ($p = .038$) were increased compared to controls, and resting heart rate ($p = .020$) compared to Alzheimer Disease patients. Behavioural variant frontotemporal dementia was associated with decreased activity levels compared to controls ($p = .002$) and increased resting energy expenditure ($p = .045$) and total energy expenditure ($p = .035$). Increased resting heart rate correlated with behavioural (Cambridge Behavioural Inventory) and cognitive measures (Addenbrooke’s Cognitive Examination). Increased resting heart rate in behavioural variant frontotemporal dementia correlated with atrophy involving the mesial temporal cortex, insula, and amygdala, regions previously suggested to be involved exclusively in social and
emotion processing in frontotemporal dementia. These neural correlates overlap the network involved in eating behaviour in frontotemporal dementia suggesting, a complex interaction between eating behaviour, autonomic function and energy homeostasis. As such the present study suggests that increased heart rate and autonomic changes are prevalent in behavioural variant frontotemporal dementia (bvFTD), and are associated with changes in energy expenditure. An understanding of these changes and neural correlates may have potential relevance to disease progression and prognosis.
Introduction

Traditionally Frontotemporal dementia (FTD) has been viewed as a syndrome characterised by behavioural and cognitive changes, although increasingly it is being recognised that there is involvement of networks that affect physiological processing including somatosensory processing including pain and temperature (Fletcher et al., 2015a; Fletcher et al., 2015b), autonomic processing (Ahmed et al., 2015a; Guo et al., 2016), and neuroendocrine and metabolic changes (Ahmed et al., 2014b; Ahmed et al., 2015b). In behavioural variant frontotemporal dementia (bvFTD), eating behavioural changes are common, including hyperphagia, increased sweet preference and changes in food preference that may be associated with increased body mass index (BMI), dyslipidaemia and insulin resistance (Ahmed et al., 2014b). It has been suggested that given the prevalence of these eating behavioural changes, alterations in BMI are less than expected for the increased energy intake, suggesting changes in energy expenditure (Woolley et al., 2007; Ahmed et al., 2016a).

In several neurodegenerative diseases it is established that there are changes in metabolic parameters. One such condition is ALS, which shares a clinical and pathological overlap with FTD and where consistent changes have been found (Ahmed et al., 2016b), including increased resting energy expenditure in up to 50% of patients (Bouteloup et al., 2009; Vaisman et al., 2009). It has also been suggested that the hypermetabolic state (defined as increased energy expenditure) is intrinsically linked to the process of neurodegeneration with several animal models of TDP-43 and the C9ORF72 gene expansion exhibiting hypermetabolism and weight loss (Dupuis et al., 2004; Chiang et al., 2010; Shan et al., 2010; Xu et al., 2010; Koppers et al., 2015).

Given the significant overlap between FTD and ALS at a clinical, pathological and genetic level, it seems plausible that changes in energy expenditure may also be present in FTD (Ahmed et al., 2016b). In addition, the changes in appetite appear to exceed the minor increments in BMI and weight gain seen in bvFTD, suggesting increased energy expenditure may also contribute to the body weight changes seen in patients (Woolley et al., 2007; Ahmed et al., 2014a). This is also suggested by the
fact that in studies measuring caloric intake in FTD, adapted from obesity research, BMI does not correlate with caloric intake, suggesting other factors are at play (Ahmed et al., 2016a). Energy expenditure, which includes basal metabolic rate (amount of energy expended at rest) and active energy expenditure (a combination of activity levels and heart rate), has not been investigated in bvFTD. Intrinsically linked with energy expenditure are potentially alterations in autonomic activity including heart rate, heart rate variability, and sympathetic and parasympathetic drive (Messina et al., 2013). Changes in the autonomic nervous system, particularly in the sympathetic nervous system have also been proposed to affect glucose and fat metabolism (Nonogaki, 2000; Penicaud et al., 2000). Increases in heart rate have been found to predict an increase in metabolic rate and energy expenditure, via an increase in circulatory rate and oxygen consumptions (Berggren and Hohwu Christensen, 1950).

Measurement of energy expenditure in free-living individuals is challenging. In this study, we used digital heart rate/activity monitoring (Brage et al., 2004; Brage et al., 2005; Crouter et al., 2008) to examine changes in heart rate (rest, stressed and sleep), activity levels and energy expenditure and the potential correlations that this has to autonomic function in a large group of bvFTD patients, compared to a disease comparison group (Alzheimer’s disease, AD) and healthy controls. This approach has been used previously in genetic obesity research but not in patients with neurodegeneration (Pearce et al., 2013). The potential neurobiological underpinnings of increases in heart rate were further examined using structural MRI imaging to provide insight into the neural correlates controlling energy expenditure and autonomic function in FTD.
Methods

Participants
Thirty-two patients with dementia (19 bvFTD, 13 AD) were recruited from Forefront, Neuroscience Research Australia. These individuals were compared with 16 age- and sex-matched healthy controls. All patients underwent neurological review, cognitive assessment and met current clinical diagnostic criteria for probable bvFTD or AD (McKhann et al., 2001; Gorno-Tempini et al., 2011; McKhann et al., 2011; Rascovky et al., 2011). Disease severity was established using the Frontal Rating Scale (FRS) (Mioshi et al., 2010). Controls were recruited from the Neuroscience Research Australia Volunteer database. Healthy controls scored above 88/100 on the Addenbrooke’s Cognitive Examination-III (Hsieh et al., 2013) and 0 on the sum of boxes score of the Clinical Dementia Rating scale (Morris, 1993). Exclusion criteria for patients and controls included concurrent psychiatric disturbance, other neurodegenerative conditions or neurological disorders and/or history of substance abuse.

Patient medical history and medications
Patients medical records and list of medications were obtained from their general practitioner. Given that the study measured heart rate variations, patients with a known cardiac rhythmic disorder e.g. atrial fibrillation, supraventricular tachycardia or conduction delays were excluded from the study (2 patients in total – 1 bvFTD and 1 AD patient). Patients’, their carers and controls were asked about their current smoking status and alcohol intake.

Ethics
This study was approved by the South Eastern Sydney Local Health District and the University of New South Wales human ethics committees. Written informed consent was obtained from each participant and/or their primary caregiver.

Physiological measurements: Actiheart device
Participants were fitted with the Actiheart device (CamNtech, Cambridge, UK) a compact device designed to quantify heart rate, activity and energy expenditure (Brage et al., 2004; Brage et al., 2005; Crouter et al., 2008). The Actiheart has two clips which are attached directly to standard ECG electrodes. One electrode was attached to V1 on the chest (4th right intercostal space) and the second electrode was placed 10 cm away on the left mid-clavicular line. The number of R waves detected is recorded at 15-second epochs and from this the heart rate is derived.

Simultaneously, an internal triaxial accelerometer senses the frequency and intensity of the participant’s torso movements, including walking and pacing from which activity counts are derived. When placed in short term mode, the Actiheart measures heart rate variability, heart rate and inter-beat interval (IBI) of the heart rate, with an epoch length of 15 seconds. Long term recordings in long term mode provide mean heart rate and activity levels over an epoch of 15 seconds and recordings can be made for up to 11 days (Brage et al., 2004; Brage et al., 2005; Crouter et al., 2008).

**Measurement of heart rate**

To measure resting and stressed heart rate participants wore the Actiheart in short term recording mode for a period of 6 hours following a standard protocol, described briefly. After arriving fasted (10 hours) and an initial period of introduction patients were given a set breakfast that measured caloric intake (Ahmed et al., 2016a), no caffeine or tea was included in this breakfast to avoid their chronotropic effects on heart rate. Participants were then asked to rest in a lounge environment and their resting heart rate was obtained over a period of 30 minutes. Following this, participants were then taken into a room and took part in 2 hours of cognitive testing. The initial 30 minutes of this period was taken as the stressed heart rate. Resting and stressed heart rates and measures of autonomic function were obtained after entering the beat-to-beat RR interval data obtained by the Actiheart into Kubios HRV, an advanced and easy to use software for heart rate variability (HRV) analysis (Tarvainen et al., 2014). The following measures were obtained: the root mean squared of successive differences (RMSSD), which is a measure of vagal control of the heart (DeGiorgio et al., 2010); the low frequency (LF), which corresponds to the 0.10Hz slow fluctuations of arterial pressure and reflects sympathetic and parasympathetic tone; the high frequency (HF) which corresponds to ~0.25 Hz fluctuations and is a measure of respiratory sinus arrhythmias and can be considered
an index of vagal modulation; and the LF/HF ratio which is used to indicate balance between sympathetic and parasympathetic tone.

**Long term activity**

Following the short term analyses, participants were fitted with the Actiheart in long term mode and asked to wear this at home for 7 days to provide continuous heart rate and activity monitoring. The participants wore the device continuously and were allowed to shower with the device. Carers were given instructions to refit the device if it became loose or was removed. From the long-term recording, sleeping heart rate and activity counts were calculated.

**Measurement of sleeping heart rate**

Sleeping heart rate was calculated over a period of 1 night. For each participant, the 1 night was selected from the 7 day long term recording where a period of recording of uninterrupted sleep was obtained, between midnight and 5 am where no activity was detected. From this period, the average sleeping heart rate, minimum and maximum heart rate was calculated for each participant. Investigators were blinded to the patient ID and diagnoses for this selection. Sleeping heart rate was calculated over a period of 1 night. For each participant, the 1 night was selected from the 7 day long term recording where a period of recording of uninterrupted sleep was obtained, with the most reliable recording. The patient ID and diagnoses was blinded for this selection. This was defined as a period between midnight and 5 am where no activity was detected. From this period, the average sleeping heart rate, minimum and maximum heart rate was calculated for each participant.

**Measurement of activity over 24 hours**

An average activity count over 24 hours was calculated for each participant. This was obtained by selecting a 24-hour period in the 7 day long-term recording where continuous recording was available for each patient. This was found to be day 2 in each patient as the Actiheart had been firmly attached and had not been removed, which tended to occur as the long term recording proceeded. The average activity counts for each patient over these 24 hours was obtained and expressed as an activity count per 24 hours. Significance levels between group means were examined after correcting for age and sex.
Measurement of energy expenditure

The Actiheart measures heart rate and activity simultaneously and these data are transferred to the Actiheart software which uses a validated branched model equation (Brage et al., 2004; Brage et al., 2005) to derive active energy expenditure for each epoch using a combination of heart rate and activity. Using the branched model equation, group Cal JAP2007 (CamNtech, Cambridge, UK) measures of daily energy expenditure were calculated for each participant each day for 7 days and an average over this period obtained. The following measures were obtained: Activity Energy expenditure (AEE) derived from the branched model equation, which includes a combination of heart rate and activity measures; Resting energy expenditure (REE) derived from the Schofield equation, designed to measure basal metabolic rate adjusted for weight (Schofield, 1985); Dietary induced thermogenesis (DIT), estimated as 10% of total energy expenditure; Total energy expenditure (TEE) = REE + AEE + DIT; Physical activity level (PAL) = TEE/REE.

Behavioural measurements

In addition to measurements of heart rate variability, activity and energy expenditure, changes in eating behaviour were measured using caregiver-based questionnaires: the Appetite and Eating Habits Questionnaire (APEHQ) (Ikeda et al., 2002; Ahmed et al., 2014a) and the Cambridge Behavioural Inventory (CBI) (Bozeat et al., 2000). These surveys were completed on the same day the short term recordings were obtained and were felt to be representative of intake over the proceeding 7 days when the long term recordings were obtained. The APEHQ provides measures of nicotine and alcohol consumption. Height and weight were measured barefoot and body mass index (BMI) calculated (weight in kilograms/height in metres squared).
**Imaging**

**MRI acquisition and preprocessing**

All participants underwent whole brain structural MRI with a 3 T Phillips scanner using a standard 8-channel head coil. 3D high-resolution turbo field echo T1-weighted sequences were acquired with the following parameters: coronal orientation, matrix $256 \times 256$, 200 slices, 1 mm$^2$ in-plane resolution, slice thickness 1 mm, echo time/repetition time $2.6/5.8$ ms, flip angle $\alpha=8^\circ$. MRI scans were obtained on the same day as the physiological and behavioural assessment.

Before analyses, the two T1 volumes were merged and averaged to increase the signal to noise ratio and the grey matter-white matter contrasts in brain structures. FreeSurfer software, version 5.3.0 (http://surfer.nmr.mgh.harvard.edu) was used for surface-based cortical processing (Dale et al., 1999; Fischl et al., 1999) using standard methods (Fischl and Dale, 2000). Cortical thickness was smoothed with a 20 mm full-width at half-height Gaussian kernel. This level of blurring kernel was chosen to reduce the impact of imperfect alignment between cortices and thereby improve the signal-to-noise ratio (Lerch and Evans, 2005).

In addition, the following subcortical structures were automatically segmented and extracted for both hemispheres: thalamus, caudate, putamen, globus pallidus, hippocampus, amygdala, and nucleus accumbens. For these subcortical structures, measurements from both hemispheres were averaged and adjusted for total intracranial volume, in line with previous methodology (Voevodskaya et al., 2014).

All the resulting images were visually inspected and manually corrected in the event of tissue segmentation errors. One bvFTD patient and 2 healthy controls were excluded due to excessive surface or subcortical segmentation errors. Thus, 18 bvFTD, 13 AD and 14 healthy controls were included in the imaging analyses.

**Statistical analyses**

**Demographic and physiological variables**
Analyses were conducted using IBM SPSS statistics (version 21.0). Kolmogorov-Smirnov tests were run to determine suitability of variables for parametric analyses. One-way analyses of variance (ANOVA), followed by Tukey post hoc tests, were used to determine group differences in demographic and clinical variables (age, ACE-R). Categorical variables were analyzed using chi-square analyses. Independent t-tests were used to determine differences between bvFTD and AD for disease duration, abnormal behaviour (total CBI, CBI behavioural) and eating behaviour (APEHQ, CBI eating, and BMI) \((p \leq 0.05 \text{ regarded as significant})\). Measurements of heart rate (resting and stressed), autonomic function (resting and stressed LF, HF, RMSSD after log transformation), activity counts and energy measures (REE, AEE, DIT, PAL) were also explored using ANOVA, followed by Tukey post hoc tests. The relationship between resting heart rate and disease duration, BMI, eating behaviour (APEHQ total score) cognitive status (ACE-III) and behavioural measures (CBI total, eating and behavioural) were further explored using Pearson rank correlations corrected for multiple comparisons \((p \leq 0.01 \text{ regarded as significant})\).

**Imaging data analyses**

For cortical thickness, sets of vertex-by-vertex analyses were performed using general linear models aimed to examine differences in cortical thickness between groups and then to estimate the neural correlates for the physiological variables where bvFTD showed significant differences with both AD and healthy controls (resting heart rate and stressed heart rate). In the first set of analyses, overall cortical thickness of both hemispheres was modelled including cortical thickness as a dependent variable and group (bvFTD, AD, healthy controls) as an independent variable. In the second set of analyses, we created separate linear models, one for each physiological variable under examination. Each model included the following repressors: group (bvFTD, AD, healthy controls), the physiological variable (resting heart rate, stressed heart rate) and the interaction between group and the physiological variable. To determine physiological associations with cortical thickness specific to diagnostic group, we focused on the interaction effect between each diagnosis and each physiological variable. Correlations between physiological variables and cortical thickness were investigated first by combining all participants (behavioural variant FTD, Alzheimer’s disease, controls) and then in each patient group combined with controls, to identify neural correlates of resting and stressed heart rate to each patient group.
Since the groups were matched at baseline for age, sex and duration of disease, no covariates were included in the models. Statistical significance was set at $p = 0.001$ uncorrected for multiple comparisons. In addition, we used a conservative cluster extent threshold of $k > 50 \text{ mm}^2$. This approach is designed to minimize Type I error while balancing the risk of Type II error (Lieberman and Cunningham, 2009).

For the subcortical regions, group comparisons of subcortical volumes between bvFTD, AD and healthy controls were performed using ANOVA. Post hoc analyses were corrected for multiple comparisons using a Sidak adjustment. Next, in order to uncover the subcortical grey matter correlates of resting heart rate and stressed heart rate, correlations were investigated using the same approach outlined above. Pearson two-tailed correlational analyses were conducted with Bonferroni correction for multiple comparisons ($p < \alpha/k = .007$).

Region of interest analyses

In addition to the whole-brain analyses, a set of cortical regions of interest (ROI) were selected and computed and averaged from the regional parcellations provided by FreeSurfer for both hemispheres. These regions were selected according to previous findings in the literature examining associations between autonomic function (e.g., pain and temperature and heart rate) and brain regions in bvFTD and AD and normal controls (Critchley et al., 2003; Jones, 2011; Fletcher et al., 2015a). The regions selected included the prefrontal, mesial temporal and anterior cingulate cortices, and the insula. Details on the computation of these measurements can be found in Supplementary Table S1. Pearson two-tailed correlations were used to examine associations between these ROIs and the resting and stressed heart rate. These analyses were Bonferroni corrected to control for multiple comparisons ($p < \alpha/k = .0125$).
Results

Participants groups were representative of the diseases studied and did not differ in sex distribution, age or disease duration (Table 1, all \( p \) values > 0.365). Group differences were observed on measures of cognition (ACE-III), behavioural measures and eating behaviour (Table 1) and were in keeping with the known behaviour of the diagnostic groups. On the ACE-III as expected the patient groups scored lower than controls \( (p < .001) \). The bvFTD group was more functionally impaired relative to AD (FRS; \( t = 3.3, p = .03 \)). The bvFTD group as expected scored higher than the AD group on the total CBI score \( (t = 3.6, p = .001) \), and CBI behavioural score \( (t = 4.1, p < .001) \).

Medications, smoking and alcohol intake (Table 1)

As expected, a higher number of AD patients were on cholinesterase inhibitors (9 patients) compared to the bvFTD (2 patients) and control (no patient) groups. There was no difference in the number of patients treated with a medication likely to affect heart rate and cardiac conduction (e.g. beta blocker, calcium channel blocker) between the groups. One bvFTD patient was on stable and adequate thyroxine treatment. Two bvFTD patients and 2 control subjects were current smokers. Eight bvFTD patients carers reported that they consumed alcohol normally, less than weekly in 4 and several times per week in 4. Ten control subjects reported alcohol consumption, 4 less than weekly and 6 several times a week. Five AD patients reported alcohol intake regularly, 2 several times a week and 3 less than weekly. No patient or control participant stated that they consumed more alcohol than the recommended amount by the Australian National Health and Medical research council.

Eating behaviour and BMI

On both the APEHQ and CBI eating score and CBI eating total \( (t = 4.1, p < .001) \). The bvFTD group showed more severe eating disturbance based on caregiver surveys compared with AD \( (t = 4.1, p < .001) \). The bvFTD group had an increased BMI \( (Figure 1) \) compared to the AD \( (p = .001) \) and Control groups \( (p = .008) \) (Table 1).
Heart rate and autonomic function

Significant group differences were present for both resting (F= 8.6, p = .001) and stressed (F= 3.2, p = .047) heart rate measures. The bvFTD group (mean = 81.8 bpm) had an increased resting heart rate compared to both the control (mean= 68.5 p = .001) and AD groups (mean = 72.5, p = .020) and an increased stressed heart rate compared to the control group (bvFTD = 81.5, AD= 76.1, Control= 71.9; p = .037) (Figure 21). On measures of autonomic function (Table 2), no significant group differences were detected; however, a trend for the bvFTD group to have a decreased RMSSD value, in both resting (p = .076) and stressed states (p = .063) was present.

Correlations of resting heart rate with behavioural measures

When all groups were combined, resting heart rate was positively correlated with behavioural and eating changes as reflected by the CBI total (r = .417, p = .004), CBI behavioural (r = .451, p = .001), and total CBI eating score (r = .307, p = .01), and negatively correlated with cognitive function on the ACE-III (r = -.314, p = .01), functional ability on the FRS (r = -.308, p = .05). As in prior studies, an increased BMI correlated with behavioural changes on the CBI total (r = .369, p = .01), CBI behavioural (r = .334, p = .01), and total CBI eating score (r = .397, p = .006), and the APEHQ (r = .461, p = .01). BMI did not correlate with resting heart rate (r = .206, p = .160).

Long term Actiheart recordings

Long-term recordings over 7 days were obtained for 124 bvFTD, 10 AD, and 119 control participants to measure sleeping heart rate and activity levels. Several bvFTD patients refused to wear the Actiheart or when at home disposed of it. The patients in the subset analyses did not differ from the larger group in which short term recordings and imaging correlation were conducted.

Sleeping heart rate
As with resting and stressed heart rate, significant group differences were also detected in mean sleeping heart rate (Figure 32a) (F = 3.9, p = .032) with the bvFTD group (mean = 71.6 bpm) having an increased sleeping heart rate compared to the control group (mean = 61.5 bpm, p = .038) and a trend compared to the AD group (mean = 62.8 bpm, p = .085). No group differences (F = 1.4, p = .270) in mean minimum heart rate were detected between the bvFTD (58.9 ± 7.3 bpm), AD (54.7 ± 8.2) and control groups (55.1 ± 5.2). By contrast, the bvFTD group (100.2 ± 13.9) had an increased maximum heart rate compared to the control group (95.7 ± 14.3 bpm; F = 4.2, p = .025).

**Activity levels**

Group differences were detected on activity counts (Figure 32b) over a 24 hour period, after correcting for age and sex. Contrary to what was expected, both the bvFTD (p = .002) and AD groups (p = .05) showed significantly decreased activity counts per hour compared with the controls, suggesting particularly that the bvFTD group has reduced activity levels.

**Energy expenditure**

On examination of energy expenditure group differences were present (Table 3), with the bvFTD group having an increased resting energy expenditure (REE) compared to the control (p = .045) and AD (p = .005) groups. The bvFTD group also had an increased diet induced thermogenesis (DIT) and total energy expenditure (TEE) compared to the other groups. Despite the finding of decreased activity counts in bvFTD, no significant group differences in active energy expenditure (AEE) were observed (calculated as a combination of heart rate and activity levels), suggesting that the decreased activity counts in bvFTD may not have affected the active energy expenditure (AEE) due to the increased heart rate seen in this group.

**Imaging analyses**

**Atrophy analyses**
Group comparisons between each clinical group and controls revealed the characteristic profiles of brain atrophy previously reported as consistent with a diagnoses of bvFTD and AD. These results are presented in Supplementary Figure S1 and Supplementary Table S2. In brief, bvFTD patients showed atrophy in the insula and inferior frontal and anterior temporal cortices. In contrast, AD patients demonstrated widespread and bilateral atrophy involving parietal, temporal and to a lesser extent frontal regions, compared with controls. In addition, both clinical groups showed atrophy in all subcortical structures measured compared with controls, with the exception of the thalamus and the globus pallidus (Supplementary Table S2). The amount of atrophy in these structures was of similar magnitude in bvFTD and AD.

**Neural correlates of resting and stressed heart rate**

Unbiased whole brain analyses yielded a significant association between increasing resting heart rate and cortical thinning in the right posterior cingulate and right inferior parietal cortex when combining bvFTD and AD patients together (Figure 43).

In bvFTD but not in AD, increased resting heart rate was associated with volume reductions in the thalamus \( (r = -0.349, p = 0.05) \), caudate \( (r = -0.334, p = 0.06) \), putamen \( (r = -0.342, p = 0.05) \), hippocampus \( (r = -0.529, p = 0.002) \), amygdala \( (r = -0.353, p = 0.04) \) and nucleus accumbens \( (r = -0.446, p = 0.01) \), structures which are known in normal controls to be involved in autonomic regulation. Of these correlations, only the association between reduced hippocampal volume and increased resting heart rate survived conservative Bonferroni correction for multiple comparisons (Table 4).

Also in bvFTD but not in AD, ROI analyses uncovered significant associations between increased resting heart rate and cortical thinning in the mesial temporal cortex \( (r = -0.520, p = 0.002) \) and the insula \( (r = -0.490, p = 0.004) \). Additional correlations were also found with the prefrontal \( (r = -0.359, p = 0.04) \) and anterior cingulate cortices.
(r = .352, p = .04), again structures known to be integral to autonomic control, although these did not survive correction for multiple comparisons (Figure 54).

[INSERT FIGURE 54 HERE]

No further significant associations were found between stressed heart rate and cortical or subcortical regions in either bvFTD or AD.
Discussion

Behavioural variant frontotemporal dementia is characterized by an increased resting, stressed and sleeping heart rate compared to both AD and healthy controls. Given that changes in heart rate are indicative of changes in metabolic rate and energy expenditure (Berggren and Hohwu Christensen, 1950; Penzel et al., 2003), via the relationship between pulse rate, circulation and oxygen consumption, these changes suggest the presence of a hypermetabolic state in bvFTD. Behavioural variant frontotemporal dementia is also characterised by increased resting energy expenditure, total energy expenditure and decreased activity levels. Changes in heart rate correlate to a neural network involving the mesial temporal cortex, insula, nucleus accumbens and cingulate.

In ALS, which overlaps clinically, pathologically and genetically with bvFTD, changes in heart rate (Chida et al., 1989) and a state of hypermetabolism (Desport et al., 2001) have also been documented, with an increased heart rate on formal autonomic function testing being found secondary to increased sympathetic and decreased parasympathetic input (Chida et al., 1989). In the present study, indications of decreased vagal tone and parasympathetic input in bvFTD were also present, with a trend towards decreased RMSSD, which is a measure of heart rate variability and reflects the integrity of vagus nerve mediated control of the heart (DeGiorgio et al., 2010). (Nonogaki, 2000; Messina et al., 2013) There is good experimental evidence in rodents and humans that changes in autonomic tone induced directly or indirectly (for example through thyroid disorders) affect energy expenditure and peripheral metabolism (lipolysis) (Nonogaki, 2000; Penicaud et al., 2000; Messina et al., 2013). It is therefore readily plausible that changes in heart rate may alter energy expenditure in patients with FTD. However, this remains to be established in studies using indirect calorimetry although we note these can be quite challenging in patients with complex behavioural problems.

Anecdotally, patients with bvFTD are described as being restless with pacing behaviour or alternatively to show inertia (Piguet et al., 2009), but activity levels have
not been systematically examined. It has also been suggested that bvFTD patients may not show the degree of weight gain expected in the setting of their increased eating due to hyperactivity (Woolley et al., 2007). Here, however, we have demonstrated that bvFTD patients show decreased activity levels compared with AD patients and healthy controls. This decreased activity may be secondary to the increased apathy seen in this disorder, which has been related to atrophy in the right caudate, ventral striatum and cortical basal ganglia circuits (Eslinger et al., 2012), brain regions commonly affected in bvFTD.

In addition, bvFTD patients exhibited an increased resting energy expenditure (REE), a measure of the resting metabolic rate, and total energy expenditure. The increased REE and basal metabolic state may in part be explained by the increased body mass index seen in the bvFTD group, but may also be influenced by the presence of a hypermetabolic state. This finding is in keeping with results in ALS showing that ALS patients may show total energy expenditure well above their REE and activity levels and potentially secondary to hypermetabolism (Kasarskis et al., 2014).

Increased resting heart rate was also found to correlate with increasing cognitive impairment (lower ACE-III scores) and increasing behavioural impairment (higher CBI scores). Changes in neurodegeneration have been linked to alterations in energy homeostasis with animal models of ALS and FTD associated with weight loss and hypermetabolism (Dupuis et al., 2004; Chiang et al., 2010; Shan et al., 2010; Xu et al., 2010). Additional studies in patients with the language variants of FTD, particularly Semantic dementia may be informative. It is suspected that there may well be changes in energy expenditure in semantic dementia given that they have similar changes in BMI to bvFTD in the context of eating behavioural changes (Ahmed et al 2014) and a similar pathology to ALS (TDP-43), where energy changes are prominent (Dupuis et al., 2011; Ahmed et al., 2016b).

It may be suggested that the changes seen in heart rate in bvFTD i.e. an increased resting and stressed and sleeping heart may be secondary to environmental factors such as caffeine, nicotine or alcohol consumption, rather than physiological changes. This seems unlikely given that there was no difference in reported smoking frequency...
and alcohol consumption between the groups, with only 2 bvFTD and 2 control subjects reported to be smokers, and similar rates of reported regular alcohol consumption, which were within recommended national guidelines. It is also unlikely that caffeine and tea intake would have affected the short term heart rate recordings (resting and stressed heart rate) as patients attended fasted and then received a breakfast with no caffeine available. Caffeine and tea intake was not measured during the long term measurements and this could potentially confound the long term recordings, however this is unlikely given that resting heart was elevated in the setting of the controlled environment of no caffeine consumption for the short term recordings. When considering these results, it should be noted that changes in heart rate may potentially be related to decreased physical fitness associated with increasing disease severity, decreased activity secondary to apathy or loss of independence.

However as increases in heart rate did not correlate with BMI changes, this suggests that changes in heart rate are far more complex than just being related to physical fitness and likely represent a complex interaction between atrophy in key cortical areas affecting autonomic function, and energy expenditure, and are likely to be centrally rather than peripherally mediated. It is also unlikely that the changes in heart rate are simply related to decreased physical fitness associated with increasing disease severity, as increases in heart rate did not correlate with BMI changes, suggesting that changes in heart rate are far more complex and likely represent a complex interaction between atrophy in key cortical areas affecting autonomic function, and energy expenditure, and are likely to be centrally rather than peripherally mediated.

Whilst medications that potentially affect heart rate may affect the results of our study, there was no significant difference in use of chronotropic drugs between the groups. Cholinesterase inhibitor treatment has been linked with bradycardia in a small proportion of patients (Hernandez et al., 2009). Despite the high number of AD patients on this medication, this is unlikely to be a confounding issue in the current study as the mean resting heart rate in the AD group was above that seen in the normal control population. Medication usage that potentially affects heart rate is also unlikely to be confounding the results as there was no significant difference in use of chronotropic drugs between the groups. Cholinesterase inhibitor treatment has been linked with bradycardia in a small proportion of patients (Hernandez et al., 2009).
Despite the high number of AD patients on this medication, this is unlikely to be a confounding issue in the current study as the mean resting heart rate in the AD group was above that seen in the normal control population. (Hernandez et al., 2009)

In this study, an increased resting heart rate in bvFTD was found to correlate with atrophy of the mesial temporal cortex including hippocampus, together with the amygdala, nucleus accumbens, insula and cingulate, all structures known to be integral to autonomic control of the human body and involving the limbic system, which is known to be involved in FTD (Seeley et al., 2008; Jones, 2011). In bvFTD, pathological changes in these structures have traditionally been linked to disturbance of memory and social cognition (Galton et al., 2001; Kipps et al., 2009; Kumfor et al., 2013; Irish et al., 2014). Recently decreased cardiac vagal tone has been found in bvFTD and linked to reduced agreeableness and a network involving left-lateralized functional and structural frontoinsular and cingulate cortex deficits (Guo et al., 2016). Our findings suggest that in addition these structures may have a fundamental role in autonomic, energy expenditure and metabolic control in bvFTD.

The anterior cingulate cortex, has been shown to participate in decision making, response selection (Devinsky et al., 1995), anticipation of reward, task reinforcement (Amiez et al., 2006; Rushworth et al., 2007) and in controlling visceromotor, endocrine and skeletomotor outputs (Vogt et al., 1992), potentially via integration of cognitive with autonomic information (Critchley et al., 2001). In healthy individuals, activity of the anterior cingulate cortex has been associated with increased body mass index (Volkow et al., 2009) suggesting a role for this structure in regulating eating and metabolism. It has also been shown that the anterior cingulate cortex is related to sympathetic modulation of heart rate dissociable from cognitive and motor related activity and that focal damage to brain region can result in both an increase and decrease in heart rate (Critchley et al., 2003). Although the cingulate cortex responds to emotional stimuli, it is also metabolically active at rest (Raichle et al., 2001; Luu and Posner, 2003), suggesting a pivotal role for this brain region in the normal physiological control of the body.

Several studies and meta-analyses have shown the integral role that the amygdala plays in controlling heart and heart rate variability, particularly in times of emotional
response and threat (Thayer et al., 2012). The fact that the amygdala correlated with increased resting heart rate in bvFTD in the current study, suggests that this structure plays a role in the physiological and metabolic changes seen in bvFTD and not simply in response to emotional stimuli. The insula is involved early in the course of bvFTD (Seeley et al., 2008) and has been found on voxel-based morphometry (VBM) to correlate to pain and temperature symptoms in bvFTD, with the suggestion that it forms a network hub for sensory homeostatic signalling with the thalamus in bvFTD. (Fletcher et al., 2015a). Our findings suggest that the insula also forms an important part of the network involved in heart rate, energy expenditure, autonomic and metabolic control in bvFTD.

It is of interest that several of the structures found to correlate with increased resting heart rate namely the cingulate cortex, insula and amygdala have been found to correlate with hyperphagia and abnormal eating behaviour in bvFTD. Moreover all of these structures have connections to the hypothalamus (Kullmann et al., 2014; Ahmed et al., 2016a), which has been found to be atrophied in bvFTD and correlate with BMI measures (Ahmed et al., 2015b). This suggests a complex interaction between cortical, subcortical structures and the hypothalamus in the control of eating behaviour, heart rate and energy expenditure all of which are affected in bvFTD.

In AD, by contrast, it has been speculated that weight loss occurs with disease progression and low body weight has previously being correlated to mesial temporal cortex atrophy (Grundman et al., 1996). Further studies are required using large samples documenting longitudinal weight loss and the neural correlates to ascertain the commonalities and differences controlling weight between FTD and AD. Further studies using direct measurements of energy intake and expenditure in large numbers of patients and age-and BMI-matched controls (both normal and AD patients) longitudinally are required to assess the relative contributions of these parameters to weight change in FTD. Further studies are required using large samples documenting longitudinal changes in weight, energy expenditure and eating behaviour, and the neural correlates to ascertain the commonalities and differences controlling weight between FTD, and its variants, and AD. It will also important to examine energy expenditure between the different forms of FTD (behavioural variant versus semantic dementia), given the differences in eating behaviour that are seen.
between these conditions (Ahmed et al., 2016a). It is suspected that there may well be
changes in energy expenditure in semantic dementia given that they have similar
changes in BMI to bvFTD, in the setting of eating behaviour change (Ahmed et al.,
2014a) and a similar pathology (TDP-43) to ALS, where energy changes are
prominent (Dupuis et al., 2004; Dupuis et al., 2011). Longitudinal studies will help to
show the complex relationship between weight, eating behaviour and energy
metabolism (Ahmed et al., 2016a).

Behavioural variant frontotemporal dementia is characterized by an increased resting
and sleeping heart rate indicative of changes in metabolic rate and resting energy
expenditure (REE), which may moderate the weight gain in the setting of prominent
changes of eating behaviour. BvFTD is also accompanied by decreased activity levels
suggesting that energy expenditure changes are likely secondary to intrinsic
processes, driven by changes in heart rate, rather than by an increase in activity levels.
Changes in heart rate correlated with atrophy of cingulate and limbic systems
including the insula and amygdala, which overlap with networks known to control
eating behaviour in bvFTD. Further studies are required to document changes in heart
rate and energy expenditure across the ALS-FTD spectrum and in presymptomatic
genetic cohorts, to ascertain when changes first develop during the course of the
disease. An approach combining longitudinal clinical studies and animal models of
FTD and ALS will prove crucial. The current study is the first study to measure the
interaction between heart rate, autonomic function and energy expenditure in FTD,
using novel methods from obesity research that allow for measurements over both
short term and long term (7 days) in the patient’s normal environment. Further studies
using indirect calorimetry to measure basal metabolic rate and total energy
expenditure are warranted to further examine these interactions. An understanding of
the potential changes in energy expenditure, autonomic function and their neural
correlates including involvement of the mesial temporal cortex, cingulate cortex,
amygnda and insula in energy expenditure aids in the physiological phenotyping of
FTD and extends our knowledge of the disease beyond cognition and emotion
processing.
**Funding:** This work was supported by funding to Forefront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neurone disease, from the National Health and Medical Research Council of Australia (NHMRC) program grant (#1037746 to MK and JH) and the Australian Research Council Centre of Excellence in Cognition and its Disorders Memory Node (#CE110001021 to OP and JH) and other grants/sources (NHMRC project grant #1003159). We are grateful to the research participants involved with the ForeFront research studies. RA is a Royal Australasian College of Physicians PhD scholar and MND Australia PhD scholar. OP is an NHMRC Career Development Research Fellow (#1022684). ISF is supported by the Wellcome Trust, Medical Research Council, European Research Council, NIHR Cambridge Biomedical Research Centre and The Bernard Wolfe Endowment. AA vdK is supported by the Wellcome Trust. THC is supported by research grants from the Swiss National Science Foundation (PBLAP3-145870, P3SMP3-155318).

**Author disclosures:** The authors declare no competing financial interests

**Author contributions:**

Rebekah Ahmed: study concept, data analyses, manuscript preparation and writing.

Ramon Landin-Romero: data analyses, manuscript preparation and writing.

Tinh-Hai Collette: data analyses, manuscript preparation and writing.

Agatha van der Klaauw: data analyses, manuscript preparation and writing.

Emma Devenney: data analyses, manuscript preparation and writing.

Elana Henning: data analyses, manuscript preparation and writing.

Matthew C Kiernan: data analyses, manuscript preparation and writing.

Olivier Piguet: data analyses, manuscript preparation and writing.

Sadaf Farooqi: study concept, data analyses, manuscript preparation and writing.

John Hodges: study concept, data analyses, manuscript preparation and writing.
References


Berggren G, Hohwu Christensen E. Heart rate and body temperature as indices of metabolic rate during work. Arbeitsphysiologie 1950; 14: 255-60.


Lieberman MD, Cunningham WA. Type I and Type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci 2009; 4: 423-8.


Figure Legends

**Figure 1.** Scatter plot showing BMI values in bvFTD, AD and healthy controls
Horizontal line represents mean +/- SD. bvFTD > AD and controls (p<.001)

**Figure 2.** Resting and stressed heart rate in bvFTD, AD and healthy controls
* bvFTD > AD (p = .028), ** bvFTD > Controls (p = .037), *** bvFTD > Controls (p = .001)

**Figure 3.** Long term Actiheart results
A) Mean sleeping heart rate. *** bvFTD > controls (p = .038); B) Mean activity counts per 24 hours. * AD < Controls, bvFTD, AD (p = .05), ** bvFTD < Controls (p = .002)

**Figure 4.** Regions showing significant correlations between cortical thinning and increasing resting heart rate in bvFTD and AD in whole brain imaging analyses. Statistical significance was set at p < .001 uncorrected for multiple comparisons. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease

**Figure 5.** Significant associations between cortical thickness in preselected ROIs and resting heart rate in bvFTD and HC. No significant associations were seen in AD and HC. Statistical significance was set at p < .0125 Bonferroni corrected for multiple comparisons. bvFTD = behavioural-variant frontotemporal dementia; HC = Healthy controls

**Supplementary Figure S1.** Patterns of atrophy in bvFTD and AD versus healthy controls. Blue coloured regions show significant cortical thinning in the patient groups compared to controls (p < .05 FDR corrected). Red coloured regions show significantly increased cortical thickness in the patient group compared to controls (p < .05 FDR corrected).
### Table 1. Demographics and clinical characteristics in bvFTD, AD and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>bvFTD (n = 19)</th>
<th>AD (n = 13)</th>
<th>HC (n = 16)</th>
<th>F value</th>
<th>p value</th>
<th>Post hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (F:M)</td>
<td>8:11</td>
<td>7:6</td>
<td>6:10</td>
<td>.83†</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 ± 6.7</td>
<td>66 ± 8.2</td>
<td>65 ± 7.7</td>
<td>1.1</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.0 ± 6.9</td>
<td>23.6 ± 3.1</td>
<td>27.2 ± 5.9</td>
<td>9.6</td>
<td>p &lt; .001</td>
<td>bvFTD &gt; AD, HC</td>
</tr>
<tr>
<td>ACE-III Total (max 100)</td>
<td>67.1 ± 20.7</td>
<td>64.3 ± 11.2</td>
<td>95.1 ± 1.9</td>
<td>21.6</td>
<td>p &lt; .001</td>
<td>HC &gt; patients</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>3.5 ± 1.9</td>
<td>4.7 ± 4.5</td>
<td>-</td>
<td>.972#</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>FRS Rasch score^</td>
<td>-1.7 ± 1.2</td>
<td>-0.2 ± 1.4</td>
<td>-</td>
<td>17.7#</td>
<td>p &lt; .01</td>
<td>bvFTD &lt; AD</td>
</tr>
<tr>
<td>APEHQ Total</td>
<td>68.9 ± 38.6</td>
<td>15.1 ± 20.2</td>
<td>-</td>
<td>4.1#</td>
<td>p &lt; .001</td>
<td>bvFTD &gt; AD</td>
</tr>
<tr>
<td>CBI Total</td>
<td>86.3 ± 24.7</td>
<td>51.3 ± 27.3</td>
<td>-</td>
<td>3.6#</td>
<td>p &lt; .01</td>
<td>bvFTD &gt; AD</td>
</tr>
<tr>
<td>CBI eating Total</td>
<td>9.3 ± 3.8</td>
<td>3.2 ± 4.5</td>
<td>-</td>
<td>4.1#</td>
<td>p &lt; .001</td>
<td>bvFTD &gt; AD</td>
</tr>
<tr>
<td>Number treated with cholinesterase inhibitor (n)</td>
<td>2</td>
<td>9</td>
<td>0</td>
<td>22.2†</td>
<td>p &lt; .001</td>
<td>AD &gt; bvFTD and HC</td>
</tr>
<tr>
<td>Number treated with Beta-blocker or calcium channel blocker (n)</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>.21†</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Current Smokers (n)</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>1.7†</td>
<td>ns</td>
<td>-</td>
</tr>
<tr>
<td>Alcohol consumption (n)</td>
<td>8</td>
<td>5</td>
<td>10</td>
<td>2.1†</td>
<td>ns</td>
<td>-</td>
</tr>
</tbody>
</table>

†: p < .05
ns: Not significant
Values are expressed as mean ± standard deviation. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease; HC = healthy controls; BMI = body mass index; ACE-III = Addenbrooke’s Cognitive Examination-III; FRS = Frontotemporal dementia Rating Scale; APEHQ = Appetite and Eating Habits Questionnaire; CBI = Cambridge Behavioural Inventory; ns = not significant. †Chi-square test; # t-value; ^The FRS provides logit scores ranging from 4.12 (very mild) to -4.99 (very severe). N= number of patients normally reporting alcohol and regular smokers. All alcohol consumption was within normal guidelines (see text).
<table>
<thead>
<tr>
<th></th>
<th>bvFTD (n = 19)</th>
<th>AD (n = 13)</th>
<th>HC (n = 16)</th>
<th>F value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting LF</td>
<td>.06 ± .02</td>
<td>.07 ± .02</td>
<td>.06 ± .01</td>
<td>.38</td>
<td>ns</td>
</tr>
<tr>
<td>Resting HF</td>
<td>.20 ± .08</td>
<td>.20 ± .07</td>
<td>.26 ± .07</td>
<td>2.6</td>
<td>ns</td>
</tr>
<tr>
<td>Resting RMSSD</td>
<td>21.7 ± 11.1</td>
<td>29.2 ± 18.6</td>
<td>41.7 ± 35.1</td>
<td>2.7</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed LF</td>
<td>.08 ± .10</td>
<td>.07 ± .02</td>
<td>.07 ± .03</td>
<td>.10</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed HF</td>
<td>.21 ± .07</td>
<td>.22 ± .09</td>
<td>.22 ± .07</td>
<td>.08</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed RMSSD</td>
<td>23.3 ± 15.3</td>
<td>31.6 ± 17.9</td>
<td>41.7 ± 31.9</td>
<td>2.9</td>
<td>ns</td>
</tr>
<tr>
<td>Rested LF/HF</td>
<td>.34 ± .10</td>
<td>.35 ± .20</td>
<td>.29 ± .14</td>
<td>1.7</td>
<td>ns</td>
</tr>
<tr>
<td>Stressed LF/HF</td>
<td>.48 ± .65</td>
<td>.38 ± .17</td>
<td>.37 ± .15</td>
<td>1.8</td>
<td>ns</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± standard deviation. Statistical analyses performed on Log transformed values. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease; HC = healthy controls; LF= low frequency; HF= high frequency; RMSSD= the square root of the mean squared difference of successive beat to beat intervals and a measure of vagal control of the heart.
Table 3. Average energy expenditure (kcal) per day in bvFTD, AD and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>bvFTD*</th>
<th>AD*</th>
<th>HC*</th>
<th>F value</th>
<th>p value</th>
<th>Post hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting energy EE</td>
<td>1656.9 ± 245.0</td>
<td>1356.4 ± 170.5</td>
<td>1442.1 ± 173.7</td>
<td>6.4</td>
<td>.005</td>
<td>bvFTD &gt; HC (p = .045)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bvFTD &gt; AD (p = .005)</td>
</tr>
<tr>
<td>Active energy EE</td>
<td>676.9 ± 428.3</td>
<td>471.1 ± 278.8</td>
<td>525.1 ± 141.1</td>
<td>1.3</td>
<td>.291</td>
<td>-</td>
</tr>
<tr>
<td>Diet induced TIT</td>
<td>259.2 ± 53.6</td>
<td>202.9 ± 43.9</td>
<td>218.3 ± 24.6</td>
<td>5.0</td>
<td>.013</td>
<td>bvFTD &gt; HC (p = .035)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bvFTD &gt; AD (p = .013)</td>
</tr>
<tr>
<td>Total energy EE</td>
<td>2592.4 ± 533.9</td>
<td>2028.5 ± 440.9</td>
<td>2182 ± 246.4</td>
<td>5.0</td>
<td>.013</td>
<td>bvFTD &gt; HC (p = .035)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bvFTD &gt; AD (p = .013)</td>
</tr>
<tr>
<td>Physical activity AL</td>
<td>1.6 ± .3</td>
<td>1.5 ± .1</td>
<td>1.5 ± .1</td>
<td>.6</td>
<td>.531</td>
<td>-</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± standard deviation. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease; HC = healthy controls; REE = Resting Energy Expenditure; AEE = Activity Energy Expenditure; DIT = Dietary Induced Thermogenesis; TEE = Total Energy Expenditure; PAL = Physical activity level. *Missing data: Data missing for 7 bvFTD, 3 AD and 5 HC.
<table>
<thead>
<tr>
<th></th>
<th>Thalamus</th>
<th>Caudate</th>
<th>Putamen</th>
<th>Pallidum</th>
<th>Hippocampus</th>
<th>Amygdala</th>
<th>Accumbens</th>
</tr>
</thead>
<tbody>
<tr>
<td>bvFTD</td>
<td>-.349*</td>
<td>-.334</td>
<td>-.342*</td>
<td>-.197</td>
<td>-.529**</td>
<td>-.352*</td>
<td>-.446*</td>
</tr>
<tr>
<td>AD</td>
<td>.031</td>
<td>.173</td>
<td>.159</td>
<td>.257</td>
<td>.056</td>
<td>-.004</td>
<td>.026</td>
</tr>
</tbody>
</table>

Values as expressed in Pearson’s correlation coefficient scores. * Denotes that the correlation is significant at the 0.05 level. ** Denotes that the correlation is significant at the 0.01 level. Significant correlations after correction for multiple comparisons are highlighted in bold. bvFTD = behavioural-variant frontotemporal dementia; AD = Alzheimer’s disease. Statistical significance was set at p < .007 Bonferroni corrected for multiple comparisons.